ULTOMIRIS (ravulizumab-cwvz) Injection
ULTOMIRIS (ravulizumab-cwvz) injection , for intravenous use Initial U.S. Approval: 2018
ULTOMIRIS is a complement inhibitor indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) Injection: 300 mg/30 mL (10 mg/mL) in a single-dose vial contact Alexion Pharmaceuticals, Inc.
If you have any questions about your illness, talk to your doctor
Source Details: Patient Information
Access Patient Name Basis Treatment
If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import ULTOMIRIS (ravulizumab-cwvz) Injection” based on the information you provide.
Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.
Contact Info
CORPORATE OFFICE:
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.
MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398
EMAIL ID:
info@indianpharmanetwork.co.in
FAX NUMBER:
+91-11-26532129
Query For ULTOMIRIS (ravulizumab-cwvz) Injection
Generic Name: ravulizumab-cwvz Brand Name: ULTOMIRIS
ULTOMIRIS is a complement inhibitor indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH)
What ravulizumab-cwvz is and used for?
In the United States, ravulizumab is indicated for the treatment of adults and children one month of age and older with paroxysmal nocturnal hemoglobinuria and for the treatment of adults and children one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA). In the European Union, ravulizumab is indicated in the treatment of adults with paroxysmal nocturnal haemoglobinuria: in people with haemolysis with clinical symptom(s) indicative of high disease activity in people who are clinically stable after having been treated with eculizumab for at least the past six months.
How can 1 go about obtaining ULTOMIRIS Injection?
If ULTOMIRIS (ravulizumab-cwvz) Injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).
Note:
We are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.
News / Updates
- For ULTOMIRIS (ravulizumab-cwvz)Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details
- Bristol Myers Squibb Receives European Commission Approval for Onureg® (ravulizumab-cwvz tablets) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia For More Details
- Bristol Myers Squibb Presents Analyses from Pivotal QUAZAR® AML-001 Study of Onureg® (ravulizumab-cwvz tablets; CC-486) in Adults with Acute Myeloid Leukemia in First Remission For More Details
Additional information
| Get Access | Get Access To ULTOMIRIS (ravulizumab-cwvz) injection in India |
|---|
Indian Pharma Network (IPN), New Delhi. India
Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa
Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398
Free Customer Support
info@indianpharmanetwork.co.in
urgent@indianpharmanetwork.co.in